Jubilant Pharmova gains on completing transfer of API business to Jubilant Biosys
Jubilant Pharmova is currently trading at Rs 1047.95, up by 8.45 points or 0.81% from its previous closing of Rs 1039.50 on the BSE.
The scrip opened at Rs 1039.55 and has touched a high and low of Rs 1053.55 and Rs 1034.00 respectively. So far 1395 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1309.00 on 07-Nov-2024 and a 52-week low of Rs 823.70 on 09-Apr-2025.
Last one week high and low of the scrip stood at Rs 1069.35 and Rs 1012.75 respectively. The current market cap of the company is Rs 16717.35 crore.
The promoters holding in the company stood at 47.68%, while Institutions and Non-Institutions held 26.92% and 25.40% respectively.
Jubilant Pharmova has successfully completed the sale and transfer of its Active Pharmaceutical Ingredients (API) Business to Jubilant Biosys (JBL), a wholly-owned subsidiary of the Company on September 1, 2025, in accordance with the terms of the Business Transfer Agreement (BTA).
Earlier, the company had received approval from board of directors of the company on June 12, 2025 for the same.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
